Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 3,225 | 2,386 | 1,915 | 2,998 | 4,553 |
| Cost of Goods | 127 | 119 | 102 | 235 | 215 |
| Gross Profit | 3,098 | 2,267 | 1,813 | 2,763 | 4,338 |
| Operating Expenses | 8,249 | 9,028 | 8,554 | 8,249 | 8,787 |
| Operating Income | -5,024 | -6,642 | -6,639 | -5,251 | -4,234 |
| Other Income | -179 | 435 | 277 | -324 | -2,548 |
| Pre-tax Income | -5,203 | -6,207 | -6,362 | -5,575 | -6,782 |
| Income Tax | N/A | -1,803 | N/A | 541 | 0 |
| Net Income Continuous | -5,203 | -4,404 | -6,362 | -6,116 | -6,782 |
| Minority Interests | 26 | -32 | -8 | -47 | -19 |
| Net Income | $-5,229 | $-4,372 | $-6,354 | $-6,069 | $-6,763 |
| EPS Basic Total Ops | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| EPS Basic Continuous Ops | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 |
| EPS Diluted Total Ops | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| EPS Diluted Continuous Ops | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 |
| EBITDA(a) | $-4,773 | $-6,471 | $-6,477 | $-5,075 | $-4,058 |